Financials data is unavailable for this security.
View more
Year on year Fuso Pharmaceutical Industries Ltd had net income fall -14.20% from 1.61bn to 1.38bn despite a 8.61% increase in revenues from 51.02bn to 55.41bn. An increase in the cost of goods sold as a percentage of sales from 73.07% to 75.02% was a component in the falling net income despite rising revenues.
| Gross margin | 25.67% |
|---|---|
| Net profit margin | 2.71% |
| Operating margin | 4.22% |
| Return on assets | 2.02% |
|---|---|
| Return on equity | 4.18% |
| Return on investment | 3.50% |
More ▼
Cash flow in JPYView more
In 2024, cash reserves at Fuso Pharmaceutical Industries Ltd fell by 2.89bn. However, the company earned 628.00m from its operations for a Cash Flow Margin of 1.13%. In addition the company generated 14.00m cash from financing while 3.54bn was spent on investing.
| Cash flow per share | 440.61 |
|---|---|
| Price/Cash flow per share | 5.52 |
| Book value per share | 4,361.00 |
|---|---|
| Tangible book value per share | 4,266.66 |
More ▼
Balance sheet in JPYView more
| Current ratio | 1.35 |
|---|---|
| Quick ratio | 0.9393 |
| Total debt/total equity | 0.3825 |
|---|---|
| Total debt/total capital | 0.2767 |
More ▼
Growth rates in JPY
Year on year, growth in dividends per share remained flat while earnings per share excluding extraordinary items fell by -12.61%. Additionally when measured on a five year annualized basis, dividend per share growth is below the industry average relative to its peers, while earnings per share growth is in-line with the industry average.
| Div yield(5 year avg) | 2.93% |
|---|---|
| Div growth rate (5 year) | -2.64% |
| Payout ratio (TTM) | 38.89% |
| EPS growth(5 years) | 9.44 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 3.01 |
More ▼
